NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Alexis Roth
Conditions: HIV Infections, Opioid Use, Trauma, Psychological
Countries: United States
The goal of this study is to elicit information crucial for designing strategies to support engagement in cabotegravir, a long-acting injectable form of pre-exposure prophylaxis (PrEP) to reduce HIV risk among women who inject drugs (WWID), a population with high unmet need that has been understudied in all phases of PrEP research. The main questions this study aims to answer are: 1. How do WWID perceive long-acting injectable cabotegravir (CAB-LA) as a HIV prevention tool? 2. If and how their decisions to initiate CAB-LA as PrEP are informed by their experiences with other long-acting medications, experience with daily oral medications, and their personal circumstance (e.g., like housing or addition severity)? 3. Do PrEP outcomes (e.g., adherence) and engagement in care over time differ between WWID prescribed CAB-LA versus daily oral PrEP? The sample for this study will be derived from and ongoing prospective trial of "TIARAS," a multi-component behavioral intervention designed to reduce HIV acquisition risk among women who inject drugs (see NCT05192434).
Sex: FEMALE
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * HIV-negative cisgender female * age ≥ 18 years * speaks/reads English * reporting past 6 months day non-prescription injection drug use * enrolled in the TIARAS trial (NCT05192434) Exclusion Criteria: • Unable to provide informed consent
- Philadelphia, Pennsylvania, United States